PDX model details
| PDX ID |
156R |
| Host Strain(and Source) |
NSG Source: Monash University |
| Host Strain Immune system Humanized |
NO |
| Host Type |
Testosterone supplemented |
| Graft Site |
Renal |
Current Generation (* indicates number of generations grown in Castrate host) |
7 |
| Average PDX Generation Time (days +/- SEM) |
269 ± 52 |
| Tumour preparation |
Tumor solid |
| Tumour Characterization Technology |
Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin |
Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed |
Routine QA every 2-3 passages |
| Associated meta data |
| PDX model availability |
Yes (fixed, frozen) |
| Governance restriction for distribution |
Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements. |
| Pubmed ID |
34413304 |
| |
|
| Markers |
156R |
| AR |
Y |
| PSA |
Y |
| PSMA |
Y |
| NE |
N |
| ERG |
N |
This heatmap displays the call type of curated CNVs in the presented samples.
This heatmap displays the call type of CNVs in commonly occurred samples.
This table displays curated CNVs
|
PDX ID
|
Gene Symbol
|
CNV Log2
|
CNV Copy
|
CNV Call
|
Experiments name
|
Platform
|
Reference genome
|
| 156R |
MET |
0.718175 |
3.2902 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 156R |
BRAF |
0.718175 |
3.2902 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 156R |
EZH2 |
0.718175 |
3.2902 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 156R |
KMT2C |
0.718175 |
3.2902 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 156R |
CHD7 |
0.750493 |
3.36474 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 156R |
MYC |
0.742644 |
3.34648 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 156R |
AKT1 |
0.56485 |
2.95847 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 156R |
PIK3R1 |
-1.58906 |
0.664776 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 156R |
FANCA |
-0.778357 |
1.16606 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 156R |
NCOR1 |
-0.783025 |
1.16229 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 156R |
CDK12 |
-0.812501 |
1.13879 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 156R |
BRCA1 |
-0.811068 |
1.13992 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 156R |
NCOR1 |
-23.3694 |
0.000000185 |
homdel
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
Clinical Information
| Sample Number |
156R |
| Sample Site |
Prostate |
| Sample source |
Radical prostatectomy |
| Pathology Tumour Diagnosis |
Adenocarcinoma |
| Gleason Score |
9 |
| Primary Gleason Score |
4 |
| Secondary Gleason Score |
5 |
| Tertiary Gleason Score |
None |
| ISUP Grade Group |
5 |
| Tumour Grade |
pT3b |
| D'Amico Risk Classification |
8 |
| Tumour Volume (in cc) |
28.6 |
| Treatment Prior to Specimen Collection |
None |
| |
|
Patient Information
| Patient Number |
156 |
| Sex |
Male |
| Diagnosis |
Prostate Cancer |
| PSA at diagnosis (ng/mL) |
16.8 |
| Consent to share data |
|
| |
|
This heatmap displays the mutations of curated sequence variants.
Download
This table displays curated sequence variants
|
PDX ID
|
Gene Symbol
|
Depth
|
ALT_FREQ
|
Consequence
|
Exon
|
GnomAD_AF
|
CADD_PHRED
|
Clinvar_clnsig
|
Platform
|
Experiments Name
|
Reference
|
Library Type
|
Instrument Type
|
| 156R |
LOXL1 |
260 |
1.0 |
missense_variant |
'6/7 |
9.75E-05 |
26.4 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 156R |
ATRX |
247 |
1.0 |
missense_variant |
'7/35 |
. |
23.4 |
Pathogenic
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 156R |
SPOP |
229 |
1.0 |
missense_variant |
'6/12 |
. |
24.8 |
Likely_pathogenic
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 156R |
TP53 |
183 |
1.0 |
missense_variant |
'7/11 |
. |
25.3 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 156R |
AR |
239 |
0.99 |
missense_variant |
'1/8 |
. |
26.5 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 156R |
NEUROG2 |
400 |
0.99 |
missense_variant |
'2/2 |
. |
25.7 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 156R |
UGT1A4 |
465 |
0.65 |
missense_variant |
'1/5 |
. |
23.5 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 156R |
SPEN |
226 |
0.43 |
missense_variant |
'11/15 |
0.0003253 |
24.7 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 156R |
LATS2 |
192 |
0.4 |
inframe_insertion |
'4/8 |
. |
. |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 156R |
ARID2 |
418 |
0.33 |
frameshift_variant |
'15/21 |
. |
. |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 156R |
GRIN2A |
332 |
0.28 |
missense_variant |
'10/14 |
. |
28.2 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 156R |
NTRK1 |
499 |
0.27 |
missense_variant |
'17/17 |
. |
24 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
No information in Drug dosing Table